0001415889-23-012898.txt : 20230905 0001415889-23-012898.hdr.sgml : 20230905 20230905160523 ACCESSION NUMBER: 0001415889-23-012898 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230816 FILED AS OF DATE: 20230905 DATE AS OF CHANGE: 20230905 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Harmon Cyrus CENTRAL INDEX KEY: 0001831410 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39712 FILM NUMBER: 231235726 MAIL ADDRESS: STREET 1: C/O OLEMA PHARMACEUTICALS, INC. STREET 2: 512 2ND STREET, 4TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94107 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Olema Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001750284 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 300409740 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 780 BRANNAN STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94103 BUSINESS PHONE: (415) 651-3316 MAIL ADDRESS: STREET 1: 780 BRANNAN STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94103 4/A 1 form4a-09052023_040904.xml X0508 4/A 2023-08-16 2023-08-17 0001750284 Olema Pharmaceuticals, Inc. OLMA 0001831410 Harmon Cyrus C/O OLEMA PHARMACEUTICALS, INC. 780 BRANNAN ST SAN FRANCISCO CA 94103 true false false false 1 Common Stock 2023-08-16 4 S 0 15000 10.14 D 1023714 D The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023. On August 17, 2023, the reporting person filed a Form 4 that inadvertently excluded the weighted average sale price for the transaction. This amendment is being filed solely to report that the weighted average sale price for the transaction reported was $10.14, and the range of prices were between $9.765 and $10.65. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. /s/ Shane Kovacs, Attorney-in-Fact 2023-09-05